¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fibrin abnormality"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® fibrin ÇÑ±Û ¼¶À¯¼Ò
¼³¸í   
  Çǰ¡ ±»À» ¶§ ¼¶À¯¼Ò¿¡ Æ®·ÒºóÀÌ ÀÛ¿ëÇÏ¿© »ý±â´Â ¼¶À¯ °°Àº ´Ü¹éÁú. ¹«»öÀ̳ª ¿¯Àº È²»öÀ» ¶í °íü·Î, ¹°¿¡ Àß ³ìÁö ¾ÊÀ¸¸ç Ç÷±¸¿Í ¾ûŰ¾î ÇǸ¦ ±»°Ô ÇÏ¿© ÃâÇ÷À» ±×Ä¡°Ô ÇÑ´Ù.
¿µ¹® developmental abnormality ÇÑ±Û ¹ß´ÞÀÌ»ó
¼³¸í   
  ¹ß´Þ°úÁ¤, Áï ¼öÅ·κÎÅÍ »çÃá±â³ª ¾î¸¥ÀÌ µÇ¾î ¼º¼÷ÀÌ µÉ ¶§±îÁö »çÀÌ¿¡ ¾î´À ½Ã±â¿¡¼­ »ý±â´Â ÀÌ»óÀÌ´Ù. ±×·¯³ª Á¼Àº Àǹ̷δ ¼öźÎÅÍ Ãâ»ý±îÁöÀÇ ±â°£¿¡ »ý±ä ÀÌ»ó Áï ¼±ÃµÀÌ»óÀ» ÀǹÌÇÑ´Ù. ¼±ÃµÀÌ»ó(congenital abnormality)°ú µ¿ÀǾî.
¿µ¹® chromosome abnormality ÇÑ±Û ¿°»öüÀÌ»ó
¼³¸í   
  ¿°»öüÀÇ ¼ö³ª ±¸Á¶ÀÇ ÀÌ»ó. ÀÌ»óÀÌ »ý±ä ¼¼Æ÷³ª °³Ã¼´Â À¯ÀüÀûÀΠÀÌ»óÀ» ÀÏÀ¸ÄÑ »ç¶÷ÀÇ °æ¿ì, ´Ù¿î ÁõÈıº-ÅͳʠÁõÈıº µûÀ§ÀÇ ¿©·¯ °¡Áö ÇüÅ·Π³ªÅ¸³­´Ù.
¿µ¹® abnormality, anomaly ÇÑ±Û ÀÌ»ó, ºñÁ¤»ó
¼³¸í   
  Á¤»óÀ» ¹þ¾î³­ ¼ºÁú È¤Àº »ç½Ç. anomaly, aberration µîµµ ÀÌ»ó »óŸ¦ ³ªÅ¸³»´Â °ÍÀÌÁö¸¸ abnormality°¡ °¡Àå ³ÐÀº ÀǹÌÀÇ ÀÌ»óÀÌ´Ù. anomaly´Â º¸Åë ¼±ÃµÀû ÀÌ»óÀ» ÀǹÌÇϸç, aberrationÀº ¸Ç ´«À¸·Î º¸ÀÌÁö ¾Ê´Â ÀÌ»óÀ» ÀǹÌÇϴ °æ¿ì°¡ ¸¹´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò, ÇǺ기
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°, ÇǺ기ºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü, ÇǺ기Ç÷Àü
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
  • abnormality
    ÀÌ»ó, ºñÁ¤»ó
  • chromosomal abnormality
    ¿°»öüÀÌ»ó
  • developmental abnormality
    ¹ß´ÞÀÌ»ó
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • motor abnormality
    ¿îµ¿ÀÌ»ó
  • metabolic abnormality
    ´ë»çÀÌ»ó
  • nailfold capillary abnormality
    ¼ÕÅéÁÖ¸§¸ð¼¼Ç÷°üÀÌ»ó
  • positional abnormality
    À§Ä¡ÀÌ»ó
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • abnormality
    ÀÌ»ó, ºñÁ¤»ó
  • chromosomal abnormality
    ¿°»öüÀÌ»ó
  • motor abnormality
    ¿îµ¿Àå¾Ö
  • positional abnormality
    À§Ä¡ÀÌ»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
  • abnormality
    ÀÌ»ó, ºñÁ¤»ó
  • chromosome abnormality
    ¿°»öüÀÌ»ó
  • developmental abnormality
    ¹ß´ÞÀÌ»ó
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • metabolic abnormality
    ´ë»çÀÌ»ó
  • motor abnormality
    ¿îµ¿Àå¾Ö
  • nailfold capillary abnormality
    ¼ÕÅéÁÖ¸§¸ð¼¼Ç÷°üÀÌ»ó
  • positional abnormality
    À§Ä¡ÀÌ»ó
  • protonflow abnormality
    ¾çÀÚÈ帧ÀÌ»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • Fibrin-stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­)
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
  • abnormality
    ºñÁ¤»ó
  • abnormality by infection
    °¨¿°±âÇü
  • abnormality of cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ëÀÌ»ó
  • abnormality of conduction
    ÀüµµÀÌ»ó.
  • abnormality of organ
    ±â°üÀÌ»ó
  • abnormality of tissue
    Á¶Á÷ÀÌ»ó
  • growth abnormality
    ¹ßÀ°ÀÌ»ó.
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • positional abnormality
    À§Ä¡ÀÌ»ó(êÈöÇì¶ßÈ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin abnormality
    ¼¶À¯¼ÒÀÌ»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carmine fibrin
    Ä«¸£¹Î¼¶À¯¼Ò(¡­àéë«áÈ).
  • crystal fibrin
    °áÁ¤¼¶À¯¼Ò, ¼öÁ¤Ã¼¼¶À¯¼Ò(¡­àéë«áÈ).
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ), È­À̺기.
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«, ¼¶À¯¼ÒÀÀ°í
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«(¡­ëêÎÔ).
  • fibrin degradation product
  • fibrin degradation products =fDP
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin stabilizing factor =FSF
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­), ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤ÀÎÀÚ, ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
  • myogen fibrin
    ¹Ì¿À°ÕÈ­À̺기.
  • abnormality
    ºñÁ¤»ó
  • abnormality by infection
    °¨¿°±âÇü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Abnormality by infection
    °¨¿°±âÇü
    [¿¾ ¿ë¾î] °¨¿°ºñÁ¤»ó
  • Abnormality of organ
    ±â°üÀÌ»ó
    [¿¾ ¿ë¾î] ±â°üÀÌ»ó
  • Abnormality
    ºñÁ¤»ó
    [¿¾ ¿ë¾î] ºñÁ¤»ó
  • Growth abnormality
    ¼ºÀåÀÌ»ó
    [¿¾ ¿ë¾î] ¼ºÀåÀÌ»ó
  • Abnormality of tissue
    Á¶Á÷ÀÌ»ó
    [¿¾ ¿ë¾î] Á¶Á÷ÀÌ»ó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • fibrin monomer
    ¼¶À¯¼Ò ´Ü·®Ã¼(àéë«áÈÓ¤Õáô÷)
  • fibrin polymer
    ¼¶À¯¼Ò ÁßÇÕü(àéë«áÈñìùêô÷)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • insoluble fibrin
    ºÒ¿ë¼º(ÝÕéÁàõ) È­À̺기
  • soluble fibrin
    "°¡¿ë(ʦéÁ)ÇǺ기, °¡¿ë ¼¶À¯¼Ò(ʦéÁàéë«áÈ)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò, È­À̺기
  • fibrin plug
    È­À̺기ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin sealant
    ¼¶À¯¼Ò¹ÐÆóÁ¦(¹ÐºÀÁ¦)
  • abnormality
    ÀÌ»ó, ÀÌ»ó¼º
  • developmental abnormality
    ¹ßÀ°ÀÌ»ó
  • growth abnormality
    ¹ßÀ°ÀÌ»ó
  • proton flow abnormality
    ¾çÀÚÀ¯µ¿ÀÌ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SFC soluble fibrin complex; soluble fibrin-fibrinogen complex; spinal fluid count
FSF Fibrin Stabilizing Factor(Factor XIII)
FSP Fibrin Split Product
  = FDPs
FbDP fibrin degradation products
FBP femoral blood pressure; fibrin breakdown product; folate-binding protein; fructose-1, 6-biphosphatas...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SCIWORA Spinal Cord Injury Without Radiographic Abnormality
WMA Wall motion abnormality
FDP Fibrin Degradation Product
FbDP Fibrin Degradation Products
FS Fibrin Sealant
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • crystal fibrin
    °áÁ¤ ¼¶À¯¼Ò, ¼öÁ¤Ã¼ ¼¶À¯¼Ò
  • fibrin bodies of pleura
    È丷 ¼¶À¯ ¼Òü
    È丷°­ ±âÀúºÎ±Ù¿¡ ÀÖ´Â °¡µ¿¼º ¶Ç´Â Á¡Âø¼º, ±¸»ó, µ¿Áú¼º, ±×¸®°í ÇѰ谡 ¸íÈ®ÇÑ À¯¹éü·Î¼­, È丷 »ïÃâ¾×, ±âÈä ¶Ç´Â Ç÷±âÈäÁõ¿¡¼­ ÀÌÂ÷ÀûÀ¸·Î ¹ß»ýÇÑ´Ù.
  • fibrin plug
    È­À̺기 ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin thrombus
    È­À̺êÁø Ç÷Àü
  • abnormality
    ÀÌ»ó¼º, ºñÁ¤»ó, ÀÌ»ó, ±âÇü
    µ¿ÀǾî=abnormity. 1. ºñÁ¤»óÀûÀÎ ¼ºÁúÀ̳ª »ç½Ç.
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • abnormality of organ
    ±â°ü ÀÌ»ó
    Æó, ½ÉÀå, °£Àå, ÃéÀå, ½ÅÀå µî°ú °°Àº ±â°üÀÇ Çüųª ¼ö°¡ Á¤»óÀûÀÌÁö ¾ÊÀº »óÅÂ.
  • autosomal abnormality
    »ó¿°»öü ÀÌ»ó
  • behavioral abnormality
    Çൿ ÀÌ»ó
    µ¿ÀǾî=behavioral disorder.
  • chromosome abnormality
    ¿°»öü ÀÌ»ó
  • functional abnormality
    ±â´ÉÀû ÀÌ»ó
  • hematologic abnormality
    Ç÷¾× ÀÌ»ó, Ç÷¾× Áúȯ
  • movement abnormality
    ¿îµ¿ ÀÌ»ó
  • other abnormality
    ±âŸ ÀÌ»ó
  • positional abnormality
    À§Ä¡ ÀÌ»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
abnormality 1. The state or quality of being abnormal.
2. An anomaly, deformity, malformation, impairment, or dysfunction.
(05 Mar 2000)
snowman abnormality A radiographic appearance associated with total anomalous drainage of the pulmonary venous circulation into enlarged right and anomalous left venae cavae, that produces a globular density above the heart; the silhouette suggests the figure 8.
Synonym: snowman abnormality.
(05 Mar 2000)
karyotypic abnormality Abnormality in the number form or structure of chromosomes. Particular abnormalities are associated with particular sub- types of leukaemia.
(27 Sep 1997)
figure-of-8 abnormality A radiographic appearance associated with total anomalous drainage of the pulmonary venous circulation into enlarged right and anomalous left venae cavae, that produces a globular density above the heart; the silhouette suggests the figure 8.
Synonym: snowman abnormality.
(05 Mar 2000)
human fibrin foam A dry artificial sponge of human fibrin prepared by clotting with thrombin a foam of a solution of human fibrinogen; the clotted foam is dried from the frozen state and heated; used as a topical anticoagulant.
(05 Mar 2000)
fibrin <protein> The insoluble protein formed from fibrinogen by the proteolytic action of thrombin during normal clotting of blood. Fibrin forms the essential portion of the blood clot.
(12 Nov 1997)
fibrin calculus A urinary calculus formed largely from fibrinogen in blood.
(05 Mar 2000)
fibrin degradation products <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot.
Normal value is less than 10 mcg/ml (micrograms per millilitre).
They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia.
Acronym: FDP
(23 Sep 2002)
fibrin destabilase <enzyme> Hydrolyses the epsilon-(gamma-glutamyl)-lysine bonds of stabilised fibrin
Pharmacological action: fibrinolytic agents
Registry number: EC 3.4.99.-
Synonym: destabilase
(26 Jun 1999)
fibrin fibrinogen degradation products <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis.
Pharmacological action: antithrombins.
(12 Dec 1998)
fibrin foam <chemical> A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a haemostatic in surgery at sites where bleeding cannot be controlled by more common methods.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
fibrinogen-fibrin conversion syndrome <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma.
(05 Mar 2000)
fibrin-stabilizing factor <chemical> Fibrin stabilizing factor. It is a glycoprotein activated by thrombin in the presence of calcium to form factor xiiia. Factor xiii is found evenly distributed between plasma and platelets. Its function is to stabilise the formation of the fibrin polymer (clot) which culminates the coagulation cascade.
Chemical name: Blood-coagulation factor XIII
(12 Dec 1998)
fibrin thrombus A thrombus formed by repeated deposits of fibrin from the circulating blood; it usually does not completely occlude the vessel.
(05 Mar 2000)
fibrin tissue adhesive <chemical> An autologous or commercial tissue adhesive containing fibrinogen and thrombin. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, factor viii, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agent such as aprotinin. Mixing of the two components promotes clotting and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, haemostasis, and wound healing.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • abnormality
    ºñÁ¤»ó
  • abnormality
    ÀÌ»ó;º¯Ä¢;º´½Å;ºÒ±¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á